10896 Federal Register / Vol. 66, No. 34 / Tuesday, February 20, 2001 / Notices

ESTIMATED RESPONDENT BURDEN WAVES 3 THROUGH 7 (1/1/01 THROUGH 12/31/03)—Continued

Type of respondents

Estimated

number of

respondents

Estimated

number of responses per

respondent

Average time

in hours per

response

Estimated total

burden hours

Estimated annual hour burden (over 3

years)

Parents .......................................................................... 4,564 2 .92 8,398 2,799

Total estimated burden .......................................... 43,170 ........................ .54 23,323 7,774

There are no Capital Costs to report.

There are no Operating or Maintenance

Costs to report. Because of the

sensitivity of collecting data from

families in households involving

children as young as 9 years old, and

the importance of minimizing costs for

repetitive, return visits to obtain

respondent cooperation, NIDA provides

a reasonable cost incentive to reimburse

respondents for their time, as approved

by OMB.

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed revision in the data collection

is necessary for the proper performance

of the function of the agency, including

whether the information will have

practical utility; (2) the accuracy of the

agency’s estimate of the burden of the

proposed revision, including the

validity of the methodology and

assumptions used; (3) ways to enhance

the quality, utility, and clarity of the

information to be collected; and (4)

ways to minimize the burden of the

collection of information on those who

are to respond, including the use of

appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

Direct Comments To OMB

Written comments and/or suggestions

regarding the items(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time, should be directed to the:

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, DC 20503. Attention: Desk

Officer for NIH. To request more

information on the proposed project or

to obtain a copy of the data collection

plans and instruments, contact Susan L.

David, Project Officer; Division of

Epidemiology, Services, and Prevention

Research, National Institute on Drug

Abuse, 6001 Executive Blvd. Room

5153, MSC 9589, Bethesda, MD 20892–

9589; or call non-toll-free number (301)

443–6504; or fax to (301) 443–2636; or

email your request, including your

address, to: sdavid@nida.nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

March 22, 2001.

Dated: February 12, 2001.

Laura Rosenthal,

Executive Officer, NIDA.

[FR Doc. 01–4092 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Cancer Institute Director’s

Consumer Liaison Group.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: National Cancer

Institute Director’s Consumer Liaison Group.

Date: March 6, 2001.

Time: 12:30 p.m. to 2:30 p.m.

Agenda: To get updates from the working

groups and to discuss the advocates section

of the April 2001 DCLG meeting.

Place: National Cancer Institute, 6116

Executive Boulevard, Suite 300 C, Rockville,

MD 20852, (Telephone Conference Call).

Contact Person: Elaine Lee, Acting

Executive Secretary, Office of Liaison

Activities, National Institutes of Health,

National Cancer Institute, 6116 Executive

Boulevard, Suite 300 C, Bethesda, MD 20892,

301/594–3194.

Information is also available on the

Institute’s/Center’s home page:

deainfo.nci.nih.gov/advisory/dclg/delg.htm,

where an agenda and any additional

information for the meeting will be posted

when available.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: February 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–4090 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel,

Minority Institutions’ Drug Abuse Research

Development Program.

Date: March 23, 2001.

Time: 2 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Marina L. Volkov, PhD,

Health Scientist Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, National Institutes

Federal Register / Vol. 66, No. 34 / Tuesday, February 20, 2001 / Notices 10897

of Health, DHHS, 6001 Executive Boulevard,

Room 3158, MSC 9547, Bethesda, MD 20892–

9547, (301) 435–1433.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.277, Drug Abuse Scientist

Development Award for Clinicians, Scientist

Development Awards, and Research Scientist

Awards; 93.278, Drug Abuse National

Research Service Awards for Research

Training; 93.279, Drug Abuse Research

Programs, National Institutes of Health, HHS)

Dated: February 12, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–4085 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel, ‘‘Highthroughput Screening of Functional Activity

of Proteins Using Biosensor-based

Technology’’.

Date: February 15, 2001.

Time: 10 a.m. to 12 p.m.

Agenda: To review and evaluate contract

proposals.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Richard C. Harrison, Chief,

Contract Review Branch, Office of Extramural

Affairs, National Institute on Drug Abuse,

National Institutes of Health, 6001 Executive

Boulevard, Room 3158, MSC 9547, Bethesda,

MD 20892–9547, 301–435–1437.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel,

‘‘Fluorescent Probes’’.

Date: March 1, 2001.

Time: 9 a.m. to 1 p.m.

Agenda: To review and evaluate contract

proposals.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892.

Contact Person: Eric Zatman, Contract

Review Specialist, Office of Extramural

Affairs, National Institute on Drug Abuse,

National Institutes of Health, DHHS, 6001

Executive Boulevard, Room 3158, MSC 9547,

Bethesda, MD 20892–9547, (301) 435–1438.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.277, Drug Abuse Scientist

Development Award for Clinicians, Scientist

Development Awards, and Research Scientist

Awards; 93.278, Drug Abuse National

Research Service Awards for Research

Training; 93.279, Drug Abuse Research

Programs, National Institutes of Health,

(HHS)

Dated: February 12, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–4086 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Neurological Disorders and Stroke Special

Emphasis Panel.

Date: February 20, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Phillip F. Wiethorn,

Scientific Review Administrator, Scientific

Review Branch, NINDS/NIH/DHHS,

Neuroscience Center, 6001 Executive Blvd,

Suite 3208, MSC 9529, Bethesda, MD 20892–

9529, 301–496–9223.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.853, Clinical Research

Related to Neurological Disorders; 93.854,

Biological Basis Research in the

Neurosciences, National Institutes of Health,

HHS)

Dated: February 12, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–4087 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Neurological Disorders and Stroke Special

Emphasis Panel.

Date: March 13, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: One Washington Circle Hotel,

Presidential Board Room, One Washington

Circle, NW., Washington, DC 20037.

Contact Person: Lillian M. Publos, Ph.D,

Chief, Scientific Review Branch, NINDS/

NIH/DHHS, Nueroscience Center, 6001

Executive Blvd., Suite 3208, MSC 9529,

Bethesda, MD 20892–9529, 301–496–9223,

lp28e@nih.gov.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.853, Clinical Research

Related to Neurological Disorders; 93.854,

Biological Basis Research in the

Neuroscience, National Institutes of Health,

HHS)